Hosted on MSN26d
WINT: Patient Enrollment in SEISMiC C Trial Starts, Patent Position Expands
To position istaroxime for Phase 3 readiness, WINT launched the small Phase 2 study in SCAI Stage C. SCAI Stage C cardiogenic shock is a more severely ill patient population than the participants ...
TCTMD1mon
Trends and Outcomes of Revascularization in Cardiogenic Shock: A Matched Cohort Analysis
Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial Receive the the latest news, research, and presentations from major ...
EurekAlert!15d
ACC, AHA issue new acute coronary syndromes guideline
The American College of Cardiology and the American Heart Association today released an updated clinical practice guideline for managing individuals experiencing acute coronary syndrome (ACS). The ...
Zacks Small Cap Research on MSN10d
WINT: Advancing Lead Asset; Leveraging Strategic M&A to Potentially Shorten Timeline to Revenue Generation – Initiating Coverage
WINT READ THE FULL WINT RESEARCH REPORT Multiple Programs Focus on Unmet Needs In Cardiogenic Shock & AHF Pennsylvania-based Windtree Therapeutics, Inc. (NASDAQ:WINT) is a biopharmaceutical company ...
Yahoo Finance10d
WINT: Advancing Lead Asset; Leveraging Strategic M&A to Potentially Shorten Timeline to Revenue Generation – Initiating Coverage
To position istaroxime for Phase 3 readiness, WINT is also enrolling a small Phase 2 study in SCAI Stage C, administering istaroxime to patients with the more severe form of cardiac shock ...